

January 2018 Update

There were no changes in the portfolio this month.

I continue to believe that SNR could easily hit the low teens within the next two years and I'm being paid handsomely while waiting for this to occur.

I hold a price target over that time of \$33 for Teva.

I hold a price target of \$25 for AMC within the next two years.

BBBY should be, at a minimum, a \$30 stock. In January, it paid a dividend that netted \$108.37 after the US withholding tax of 15%.

Here are the closing prices and values of each holding as of January 31st, 2018:

6,900 SNR @\$7.66
2,000 TEVA@ \$20.41
1,300 AMC@ \$12.80
850 BBBY@ \$23.08
Cash: \$2,132.16

Account balance: \$132,064.16

Annualized return after 28 months: 12.66%